Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
JUNCTION CITY, Kan., Oct. 23, 2017 -- Ventria Bioscience Inc. today announced a $4.2 million grant from the Bill & Melinda Gates Foundation to fund development of efficient biomanufacturing for new therapeutics targeting Enterotoxigenic Escherichia coli (or ETEC), a leading bacterial cause of diarrhea in the developing world. ETEC accounts for an estimated 280 million to 400 million cases of diarrhea a year in children under five and an estimated 157,000 deaths per year. The bacterial infection also is implicated in travelers’ diarrhea.
Funding by the Gates Foundation will enable Ventria to develop its platform to produce potential ETEC treatments using Ventria’s cost-effective, scalable and safe ExpressTec technology.
“We are very pleased to receive this funding from the Bill & Melinda Gates Foundation to fight ETEC diarrheal disease, which causes widespread misery, especially among young children in lower-income countries. This initiative aims to develop a new kind of oral treatment that could be delivered economically on a large scale for use in children or adults,” said Scott E. Deeter, President and Chief Executive Officer of Ventria. “We have proven the effectiveness of our ExpressTec system for biomanufacturing synthetic colostrum proteins, such as lactoferrin and lysozyme. This new application in the global fight against ETEC adds to Ventria’s pipeline of projects with the potential to make a real difference in people’s health.”
Seymour Fein, M.D., Chief Medical Officer of Ventria, added: “The burden of gastrointestinal and diarrheal diseases in the developing world is devastating, causing hundreds of millions of people to suffer, taking the lives of the least fortunate, and draining the resources of caregivers in Africa, Asia and Latin America. ETEC infection cries out for an effective treatment that can be delivered on a large scale in areas struggling with poverty, and the Gates Foundation initiative brings hope to patients and societies afflicted by this disease. Ventria’s expertise in producing safe, high-quality proteins adds an important component to this global public health effort.”
About Ventria Bioscience Inc.
Ventria Bioscience is a biopharmaceutical company with a product pipeline targeting unmet medical needs. Ventria Bioscience’s proprietary ExpressTec biomanufacturing technology enables the development of new, safe and effective biologic products to treat gastrointestinal, autoimmune and infectious disease. For more information, visit www.Ventria.com.
For further information, contact:
Media inquiries: Dick Johnson, 913-649-8885, [email protected]
Partnering: [email protected]
